Cargando…

ELOVLs Predict Distinct Prognosis Value and Immunotherapy Efficacy In Patients With Hepatocellular Carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) is a primary malignancy of the liver with high prevalence worldwide and poor prognosis. It has been verified that elongation of very-long-chain fatty acids gene family (ELOVLs), a group of genes that responsible for elongation of saturated and polyunsaturat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yu, Pang, Shujie, Sun, Bo, Zhang, Minbo, Jiao, Xiaoxiao, Lai, Linying, Qian, Yiting, Yang, Ning, Yang, Wenzhuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334671/ https://www.ncbi.nlm.nih.gov/pubmed/35912257 http://dx.doi.org/10.3389/fonc.2022.884066

Ejemplares similares

Identification and validation of immune related core transcription factors GTF2I in NAFLD
por: Zhang, Minbo, et al.
Publicado: (2022)

Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
por: Zhong, Cheng, et al.
Publicado: (2021)

Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Reveal the Heterogeneity in the Tumor Microenvironment of Pancreatic Cancer and Analyze the Differences in Prognosis and Immunotherapy Responses of Distinct Immune Subtypes
por: Wang, Xiaoqin, et al.
Publicado: (2022)

The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma
por: Huang, Jiacheng, et al.
Publicado: (2021)

ZCCHC17 Served as a Predictive Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma
por: Liu, Fahui, et al.
Publicado: (2022)

Application of Immunotherapy in Hepatocellular Carcinoma
por: Miao, Lele, et al.
Publicado: (2021)

Glioblastoma Multiforme Tumors in Women Have a Lower Expression of Fatty Acid Elongases ELOVL2, ELOVL5, ELOVL6, and ELOVL7 than in Men
por: Korbecki, Jan, et al.
Publicado: (2022)

Phosphogluconate dehydrogenase is a predictive biomarker for immunotherapy in hepatocellular carcinoma
por: Liu, Tiantian, et al.
Publicado: (2022)

The value of metabolic LncRNAs in predicting prognosis and immunotherapy efficacy of gastric cancer
por: Du, Peizhun, et al.
Publicado: (2023)

An inflammation-related gene landscape predicts prognosis and response to immunotherapy in virus-associated hepatocellular carcinoma
por: Gao, Ying-jie, et al.
Publicado: (2023)

Leveraging various extracellular matrix levels to assess prognosis and sensitivity to immunotherapy in patients with ovarian cancer
por: Huang, Youqun, et al.
Publicado: (2023)

Upregulated LINC01667 Expression Is Correlated With Poor Prognosis in Hepatocellular Carcinoma
por: Zhang, Kainan, et al.
Publicado: (2021)

Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma
por: Peng, Xuenan, et al.
Publicado: (2023)

Corrigendum: Upregulated LINC01667 Expression Is Correlated With Poor Prognosis in Hepatocellular Carcinoma
por: Zhang, Kainan, et al.
Publicado: (2021)

Cuproptosis-related genes score: A predictor for hepatocellular carcinoma prognosis, immunotherapy efficacy, and metabolic reprogramming
por: Nie, Guilin, et al.
Publicado: (2023)

Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
por: He, Yuqing, et al.
Publicado: (2021)

Editorial: Immunotherapy in Hepatocellular Carcinoma
por: Li, Bin, et al.
Publicado: (2021)

Dominant Elongase Activity of Elovl5a but Higher Expression of Elovl5b in Common Carp (Cyprinus carpio)
por: Zhao, Ran, et al.
Publicado: (2022)

The prognosis value of CONUT and SIS score for recurrent or metastatic esophageal squamous cell carcinoma patients treated with second-line immunotherapy
por: Zhao, Xiao-Han, et al.
Publicado: (2023)

YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy
por: Hu, Jian, et al.
Publicado: (2021)

A Distinct Clinicopathological Feature and Prognosis of Young Gastric Cancer Patients Aged ≤ 45 Years Old
por: Huang, Qian, et al.
Publicado: (2021)

Identification of cuproptosis-related patterns and construction of a scoring system for predicting prognosis, tumor microenvironment-infiltration characteristics, and immunotherapy efficacy in breast cancer
por: Li, Wei, et al.
Publicado: (2022)

Cancer Stemness Associated With Prognosis and the Efficacy of Immunotherapy in Adrenocortical Carcinoma
por: Shi, Xiaoxi, et al.
Publicado: (2021)

Impact of cytotoxic T lymphocytes immunotherapy on prognosis of colorectal cancer patients
por: Zhu, Yankun, et al.
Publicado: (2023)

An Adaptive Transfer-Learning-Based Deep Cox Neural Network for Hepatocellular Carcinoma Prognosis Prediction
por: Chai, Hua, et al.
Publicado: (2021)

A distinct lipid metabolism signature of acute myeloid leukemia with prognostic value
por: Li, Ding, et al.
Publicado: (2022)

Progression in immunotherapy for advanced prostate cancer
por: Liang, Hao, et al.
Publicado: (2023)

Transcriptomic Analysis Identified Two Subtypes of Brain Tumor Characterized by Distinct Immune Infiltration and Prognosis
por: Shen, Xilin, et al.
Publicado: (2021)

Immunogenic cell death-associated biomarkers classification predicts prognosis and immunotherapy efficacy in pancreatic ductal adenocarcinoma
por: Peng, Wenguang, et al.
Publicado: (2023)

Gene therapy targeting miR-212-3p exerts therapeutic effects on MAFLD similar to those of exercise
por: Sun, Bo, et al.
Publicado: (2023)

Comprehensive analysis of the potential cuproptosis-related biomarker LIAS that regulates prognosis and immunotherapy of pan-cancers
por: Cai, Yuan, et al.
Publicado: (2022)

Therapeutic Role of ELOVL in Neurological Diseases
por: Siddiqui, Arif Jamal, et al.
Publicado: (2023)

Identification of gene signatures related to hypoxia and angiogenesis in pancreatic cancer to aid immunotherapy and prognosis
por: Li, Xiushen, et al.
Publicado: (2023)

Machine learning-based construction of a ferroptosis and necroptosis associated lncRNA signature for predicting prognosis and immunotherapy response in hepatocellular cancer
por: Zhao, Lei, et al.
Publicado: (2023)

Comprehensive characterization of ferroptosis in hepatocellular carcinoma revealing the association with prognosis and tumor immune microenvironment
por: Zhu, Jingjuan, et al.
Publicado: (2023)

The Prognostic Value of Blood-Based Biomarkers in Patients With Testicular Diffuse Large B-Cell Lymphoma
por: Yang, Jing, et al.
Publicado: (2019)

Comprehensive Characterization of Immune Landscape Based on Epithelial-Mesenchymal Transition Signature in OSCC: Implication for Prognosis and Immunotherapy
por: Zhang, Si-yuan, et al.
Publicado: (2021)

Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression
por: Zhang, Ying, et al.
Publicado: (2022)

A Novel Nine-lncRNA Risk Signature Correlates With Immunotherapy in Hepatocellular Carcinoma
por: Nie, Ye, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_efkrn0shdgp7u4k3fbca8r795e